Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,506.48
(
-1.51%
)
US TECH 100
23,484.80
(
-0.99%
)
Dow Jones
45,577.47
(
-0.96%
)
Brent Oil
105.10
(
0.00%
)
Bitcoin
68,581.80
(
-0.44%
)
News Focus
News Focus
Post# of 257268
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122806
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 192451

Tuesday, 06/16/2015 11:40:33 AM

Tuesday, June 16, 2015 11:40:33 AM

Post# of 257268
MYL takes option on ex-US rights to PULM’s PUR0200, a LAMA for COPD:

http://finance.yahoo.com/news/pulmatrix-mylan-enter-ex-u-113000190.html

Financial terms have not been disclosed.

Separately, PULM announced a new drug candidate, PUL1900, an inhaled anti-fungal drug for patients with CF (http://finance.yahoo.com/news/pulmatrix-announces-first-inhaled-anti-113000215.html ).

PULM is the product of a recent reverse merger (#msg-114559267).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today